US FDA approves Alnylam's drug for rare heart condition

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

US FDA approves Alnylam's drug for rare heart condition

, Reuters - 5:56 PM ET 3/20/2025 default

March 20 (Reuters) - U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer's ( PFE ) blockbuster Vyndaqel. (Reporting by Bhanvi Satija in Bengaluru; Editing by Alan Barona)

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.